Affordable Access

deepdyve-link
Publisher Website

Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection.

Authors
  • Łucejko, Mariusz1
  • Parfieniuk-Kowerda, Anna1
  • Flisiak, Robert1
  • 1 a Department of Infectious Diseases and Hepatology , Myedical University of Bialystok , Bialystok, Poland.
Type
Published Article
Journal
Expert Opinion on Pharmacotherapy
Publisher
Informa UK (Taylor & Francis)
Publication Date
June 2016
Volume
17
Issue
8
Pages
1153–1164
Identifiers
DOI: 10.1080/14656566.2016.1176143
PMID: 27064432
Source
Medline
Keywords
License
Unknown

Abstract

OBV/PTV/r±DSV±RBV provided an opportunity to cure almost all patients including cirrhotics and non-responders to previous therapy. This treatment is currently recommended as a first line regimen. However, there is still a need for real-world data. In coming years this medication will probably be replaced with the next DAA generation with improved characteristics such as a shorter treatment duration, improved safety and resistance profile.

Report this publication

Statistics

Seen <100 times